Figure 2
Figure 2. Response to panobinostat is independent of a functional p53 pathway. (A-B) Flow cytometry analysis of leukemic cells in peripheral blood and BLI of A/E9a;NrasG12D/p53−/− leukemia recipient mice treated with panobinostat or vehicle using the standard treatment regimen. In panel A, each data point represents an individual mouse, and horizontal bars represent mean value. ***P < .0001. (C) Kaplan-Meier survival curves of treated A/E9a;NrasG12D/p53−/− leukemia recipient mice following initiation of therapy (n = 10 for vehicle, n = 8 for panobinostat; median survival benefit 21 days, P < .0001). Dotted line indicates final day of treatment.

Response to panobinostat is independent of a functional p53 pathway. (A-B) Flow cytometry analysis of leukemic cells in peripheral blood and BLI of A/E9a;NrasG12D/p53−/− leukemia recipient mice treated with panobinostat or vehicle using the standard treatment regimen. In panel A, each data point represents an individual mouse, and horizontal bars represent mean value. ***P < .0001. (C) Kaplan-Meier survival curves of treated A/E9a;NrasG12D/p53−/− leukemia recipient mice following initiation of therapy (n = 10 for vehicle, n = 8 for panobinostat; median survival benefit 21 days, P < .0001). Dotted line indicates final day of treatment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal